Company Overview

Precigen, Inc. is a clinical-stage biotechnology company focused on advancing gene and cell-based therapies for cancer, rare diseases, and immune-related disorders. The company operates primarily within the biotechnology and genetic medicine industries, with an emphasis on developing proprietary platforms designed to improve the safety, precision, and scalability of gene expression and cellular engineering.

The company’s primary value drivers are its therapeutic development programs derived from its internal technology platforms, including AdenoVerse, UltraCAR-T, and ActoBiotics. Precigen serves oncology-focused clinical markets and specialty therapeutic areas with high unmet medical need. The company traces its origins to 1998 and was formerly known as Intrexon Corporation before rebranding as Precigen, Inc. in 2020, reflecting a strategic shift toward internally developed, clinically focused genetic medicines.

Business Operations

Precigen conducts operations through integrated research, development, and early-stage clinical programs rather than commercialized products. Its business is organized around distinct therapeutic platforms and development programs rather than traditional reporting segments. The company generates no material product revenue and is primarily funded through equity financing, collaborations, and strategic transactions.

The company operates through several subsidiaries, including Precigen ActoBio, which focuses on oral biologic therapies using engineered bacteria, and Precigen Exemplar, which provides translational research services using large animal disease models. Precigen controls proprietary gene regulation and delivery technologies and maintains internal manufacturing and research capabilities to support clinical development.

Strategic Position & Investments

Precigen’s strategy centers on advancing wholly owned clinical assets while maintaining tight control over intellectual property and development pathways. Key growth initiatives include progressing late-stage oncology programs and leveraging platform technologies to expand into additional indications. The company has historically emphasized internal innovation over large-scale external licensing.

Notable investments include the acquisition of ActoBio Therapeutics, which expanded Precigen’s presence in immune and metabolic disease research, and the continued development of UltraCAR-T technology for hematologic malignancies. The company remains focused on emerging areas of gene regulation, localized gene delivery, and non-viral or controlled viral vector systems.

Geographic Footprint

Precigen is headquartered in North America, with its corporate headquarters located in Germantown, Maryland. The company maintains research and development operations primarily within the United States, supported by specialized facilities and laboratories.

Internationally, Precigen has operational and research presence in Europe, largely through Precigen ActoBio in Belgium, which supports clinical and preclinical development activities. While the company does not have broad commercial operations globally, its clinical programs and intellectual property footprint extend across multiple regions through trials and regulatory engagement.

Leadership & Governance

Precigen was founded by Randal J. Kirk, who has played a central role in shaping the company’s long-term strategy and remains involved in governance. The current leadership team emphasizes disciplined capital allocation, platform-focused innovation, and advancing assets with clear clinical differentiation.

Key executives include:

• Helen Sabzevari – President and Chief Executive Officer
• Randal J. Kirk – Founder and Executive Chairman
• Ashley R. Still – Chief Financial Officer

The leadership philosophy centers on scientific rigor, internal control of core technologies, and advancing therapies with the potential for meaningful clinical impact.